ABSTRACT
Introduction: Currently, the therapeutic arsenal of
osteoarthritis includes several extracts of Curcuma including Flexofytol®,
a bio-optimized extract of Curcuma longa.
However, in older patients, indications for treatment might be limited by
comorbidity and polymedication. Therefore, we aimed to assess the benefits and
risks of Flexofytol®, in an older population
with comorbidities. Patients and Methods: This retrospective observational
study included 31 patients over age 70 years (medianage: 77 years, range 71 - 81)
that were treated with Flexofytol for painful osteoarthritis of the knee or
lumbar spine. These patients were initially weakened by diabetes (48%) and/or
renal insufficiency (71%), or they were taking anticoagulants (35%). The
effects of Flexofytol®, were evaluated at 0, 6
and 12 weeks with visual analog scales for pain and disability and the SF-12
Quality of Life questionnaire. Adverse effects and drug interactions of
Flexofytol®, were evaluated. In particular, we
evaluated renal function, diabetes parameters and coagulation tests. The data
were analyzed with Kruskal-Wallis and
Wilcoxon-Mann-Withney non-parametric tests. Results: Patients with
Flexofytol®, showed significant improvement:
pain improved by 50% (p = 0.0002) and functional disability improved by 33% (p =
0.0075). A series of quality of life parameters improved within the first 6
weeks of treatment and up to 3 months of treatment without impacting renal
function, metabolic parameters or coagulation tests. We observed no significant
adverse effects. Conclusion: In conclusion, our results suggested that
Flexofytol®, may be useful in the management of
painful osteoarthritis, particularly in older patients that are fragile due to
comorbidity and polymedication. These initial results must be confirmed in
future studies.
Share and Cite:
Breucker, S. , Rouvière, H. , Mélot, C. and Appelboom, T. (2017) Flexofytol
® (A Belgian Curcumin Extract) for the Treatment of Aged Patients with Osteoarthritis and Comorbidity.
Open Journal of Rheumatology and Autoimmune Diseases,
7, 167-177. doi:
10.4236/ojra.2017.74017.